Tekla Life Sciences Inves...

NYSE: HQL · Real-Time Price · USD
13.82
0.17 (1.25%)
At close: Aug 15, 2025, 3:59 PM
13.86
0.29%
After-hours: Aug 15, 2025, 04:10 PM EDT

Tekla Life Sciences Investors Income Statement

Financials in USD. Fiscal year is October - September.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Sep 30, 2024 Sep 30, 2023 Sep 30, 2022 Sep 30, 2021
Revenue
86.69M 23.52M -103.25M 65.69M
Cost of Revenue
n/a 5.24M 5.55M 6.08M
Gross Profit
86.69M 18.28M -108.8M 59.61M
Operating Income
85.3M -5.24M -104.6M 64.53M
Interest Income
1.04M 204.45K 50.09K n/a
Pretax Income
85.3M 22.35M -104.6M 64.53M
Net Income
85.3M 22.35M -104.6M 64.53M
Selling & General & Admin
1.33M 903.14K 1.08M 844.02K
Research & Development
n/a n/a -3.28 1.43
Other Expenses
n/a 22.62M 275.97K 313.69K
Operating Expenses
1.39M 23.52M 1.35M 1.16M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
1.39M 23.52M 1.35M 1.16M
Income Tax Expense
n/a n/a -2.99M -4.15M
Shares Outstanding (Basic)
28.06M 28.29M 25.68M 24.26M
Shares Outstanding (Diluted)
28.06M 28.29M 25.68M 24.26M
EPS (Basic)
3.04 0.79 -4.07 2.66
EPS (Diluted)
3.04 0.79 -4.07 2.66
EBITDA
n/a 22.35M -104.61M 64.54M
EBIT
n/a 22.35M -104.61M 64.54M
Depreciation & Amortization
n/a 27.6M 2.99M 4.14M